ClinicalTrials.gov
ClinicalTrials.gov Menu

Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program (PETRUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01786031
Recruitment Status : Completed
First Posted : February 7, 2013
Last Update Posted : February 8, 2016
Sponsor:
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary:
Toward personalised treatment in early metastatic prostate cancer based on the assessment of biomarkers in cancer tissue samples and circulating tumour cells.

Condition or disease Intervention/treatment Phase
Metastatic Castration Resistant Prostate Cancer Patients Other: metastasis biopsy Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program
Study Start Date : December 2012
Actual Primary Completion Date : January 2015
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: experimental
metastasis biopsy
Other: metastasis biopsy



Primary Outcome Measures :
  1. Biomarker [ Time Frame: assessed at the end of recruitment, up to 2 years ]
    success to evaluate at least one molecular analysis in tumor tissues (prostate and/or metastatic site) AND in CTC



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Prostate Cancer patients
  • Castration Resistant
  • Prostatic tissue available
  • Metastasis which may be biopsied

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01786031


Locations
France
Institut Gustave Roussy
Villejuif, Val de Marne, France, 94805
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov Identifier: NCT01786031     History of Changes
Other Study ID Numbers: 2012-A00668-35
First Posted: February 7, 2013    Key Record Dates
Last Update Posted: February 8, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases